Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
JBMR Plus
|
September 13, 2023
A Novel RUNX1 Genetic Variant Identified in a Young Male with Severe Osteoporosis
Tomasz J Block, Cat Shore-Lorenti, Roger Zebaze, et al.
The Lancet. Haematology
|
April 1, 2016
Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study
Anna Kalff, Nola Kennedy, Angela Smiley, et al.
British Journal of Haematology
|
June 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)
Andrew Spencer, Anna Kalff, Jake Shortt, et al.
Leukemia & Lymphoma
|
April 5, 2018
DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma
Hiu Lam Agnes Yuen, Michael Sze Yuan Low, Pasquale Fedele, et al.
British Journal of Haematology
|
September 18, 2020
Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma
Sridurga Mithraprabhu, Anna Kalff, Kate H Gartlan, et al.
Leukemia & Lymphoma
|
June 12, 2019
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)
Anna Kalff, Tiffany Khong, Sridurga Mithraprabhu, et al.
Leukemia
|
April 18, 2019
Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients
Sridurga Mithraprabhu, Rachel Morley, Tiffany Khong, et al.
Leukemia & Lymphoma
|
February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
Noemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Leukemia & Lymphoma
|
July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
JBMR Plus
|
September 13, 2023
A Novel RUNX1 Genetic Variant Identified in a Young Male with Severe Osteoporosis
Tomasz J Block, Cat Shore-Lorenti, Roger Zebaze, et al.
The Lancet. Haematology
|
April 1, 2016
Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study
Anna Kalff, Nola Kennedy, Angela Smiley, et al.
British Journal of Haematology
|
June 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)
Andrew Spencer, Anna Kalff, Jake Shortt, et al.
Leukemia & Lymphoma
|
April 5, 2018
DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma
Hiu Lam Agnes Yuen, Michael Sze Yuan Low, Pasquale Fedele, et al.
British Journal of Haematology
|
September 18, 2020
Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma
Sridurga Mithraprabhu, Anna Kalff, Kate H Gartlan, et al.
Leukemia & Lymphoma
|
June 12, 2019
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)
Anna Kalff, Tiffany Khong, Sridurga Mithraprabhu, et al.
Leukemia
|
April 18, 2019
Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients
Sridurga Mithraprabhu, Rachel Morley, Tiffany Khong, et al.
Leukemia & Lymphoma
|
February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
Noemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Leukemia & Lymphoma
|
July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Page
of 3